The Rationale for BAFF Inhibition in Systemic Lupus Erythematosus
Author:
- 26 April 2012
- journal article
- review article
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 14 (4) , 295-302
Abstract
BAFF (B-cell–activating factor) is a critical survival factor for transitional and mature B cells and is a promising therapeutic target for systemic lupus erythematosus (SLE). In 2010–2011, two phase 3 clinical trials showed that the addition of the anti-BAFF antibody belimumab to standard-of-care therapy in patients with moderately active SLE results in a better outcome at 52 weeks than standard-of-care therapy alone. Belimumab has been US Food and Drug Administration approved for the treatment of SLE, and other drugs that target BAFF are now in various stages of clinical testing. This review describes the function of BAFF and its homolog APRIL (a proliferation-inducing ligand) and addresses the rationale for the treatment of SLE with BAFF/APRIL inhibitors.Keywords
This publication has 44 references indexed in Scilit:
- BAFF/APRIL Inhibition Decreases Selection of Naive but Not Antigen-Induced Autoreactive B Cells in Murine Systemic Lupus ErythematosusThe Journal of Immunology, 2011
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusArthritis & Rheumatism, 2011
- The germinal center reactionJournal of Allergy and Clinical Immunology, 2010
- Pharmacokinetics and Biological Activity of Atacicept in Patients With Rheumatoid ArthritisThe Journal of Clinical Pharmacology, 2008
- APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cellsBlood, 2008
- TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablastsBlood, 2008
- Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trialArthritis & Rheumatism, 2007
- BAFF and MyD88 signals promote a lupuslike disease independent of T cellsJournal of Experimental Medicine, 2007
- Synthetic CpG oligodeoxynucleotides augment BAFF‐ and APRIL‐mediated immunoglobulin secretionEuropean Journal of Immunology, 2007
- TLR Stimulation Modifies BLyS Receptor Expression in Follicular and Marginal Zone B CellsThe Journal of Immunology, 2007